Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Total Liabilities (2016 - 2025)

Avanos Medical (AVNS) has disclosed Total Liabilities for 13 consecutive years, with $295.5 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 9.27% to $295.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $295.5 million through Dec 2025, down 9.27% year-over-year, with the annual reading at $295.5 million for FY2025, 9.27% down from the prior year.
  • Total Liabilities hit $295.5 million in Q4 2025 for Avanos Medical, up from $289.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $511.7 million in Q3 2022 to a low of $262.7 million in Q2 2025.
  • Historically, Total Liabilities has averaged $401.8 million across 5 years, with a median of $429.2 million in 2023.
  • Biggest five-year swings in Total Liabilities: soared 52.29% in 2022 and later crashed 39.72% in 2025.
  • Year by year, Total Liabilities stood at $333.0 million in 2021, then soared by 48.86% to $495.7 million in 2022, then fell by 7.99% to $456.1 million in 2023, then decreased by 28.59% to $325.7 million in 2024, then fell by 9.27% to $295.5 million in 2025.
  • Business Quant data shows Total Liabilities for AVNS at $295.5 million in Q4 2025, $289.7 million in Q3 2025, and $262.7 million in Q2 2025.